62 related articles for article (PubMed ID: 23016778)
1. Detection of residual/recurrent cervical disease after successful LEEP conization: the possible role of mRNA-HPV test.
Zappacosta R; Ianieri MM; Tinelli A; Gustapane S; D'Angelo C; Gatta DM; Capanna S; Rosini S
Curr Pharm Des; 2013; 19(8):1450-7. PubMed ID: 23016778
[TBL] [Abstract][Full Text] [Related]
2. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3.
Alonso I; Torné A; Puig-Tintoré LM; Esteve R; Quinto L; Campo E; Pahisa J; Ordi J
Gynecol Oncol; 2006 Nov; 103(2):631-6. PubMed ID: 16780934
[TBL] [Abstract][Full Text] [Related]
3. Pap Smear Combined with HPV Testing: A Reasonable Tool for Women with High-grade Cervical Intraepithelial Neoplasia Treated by LEEP.
Mo LZ; Song HL; Wang JL; He Q; Qiu ZC; Li F
Asian Pac J Cancer Prev; 2015; 16(10):4297-302. PubMed ID: 26028089
[TBL] [Abstract][Full Text] [Related]
4. [Early human papillomavirus testing predicts residual/recurrent disease after LEEP risk factors for predicting residual disease in high-grade squamous cervical intraepithelial neoplasia following LEEP conization].
Niu XY; Feng YK
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Mar; 46(2):321-5. PubMed ID: 25924452
[TBL] [Abstract][Full Text] [Related]
5. Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia.
Tropé A; Jonassen CM; Sjøborg KD; Nygård M; Dahl FA; Alfsen GC; Lie AK
Gynecol Oncol; 2011 Nov; 123(2):257-62. PubMed ID: 21839500
[TBL] [Abstract][Full Text] [Related]
6. HPV E6/E7 mRNA combined with thin-prep cytology test for the diagnosis of residual/recurrence after loop electrosurgical excision procedure in patients with cervical intraepithelial neoplasia.
Song Y; Zhang M; Zhang C; Du S; Zhai F
Diagn Microbiol Infect Dis; 2024 Jan; 108(1):116119. PubMed ID: 37890308
[TBL] [Abstract][Full Text] [Related]
7. [Diagnostic value of human papillomavirus E6/E7 mRNA for residue and recurrence after cervical conization].
Zhao H; Shao H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Jun; 41(6):606-11. PubMed ID: 27374445
[TBL] [Abstract][Full Text] [Related]
8. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis.
Arbyn M; Redman CWE; Verdoodt F; Kyrgiou M; Tzafetas M; Ghaem-Maghami S; Petry KU; Leeson S; Bergeron C; Nieminen P; Gondry J; Reich O; Moss EL
Lancet Oncol; 2017 Dec; 18(12):1665-1679. PubMed ID: 29126708
[TBL] [Abstract][Full Text] [Related]
9. Early human papillomavirus testing predicts residual/recurrent disease after LEEP.
Ryu A; Nam K; Kwak J; Kim J; Jeon S
J Gynecol Oncol; 2012 Oct; 23(4):217-25. PubMed ID: 23094124
[TBL] [Abstract][Full Text] [Related]
10. Role of HPV testing in the follow-up of women treated for cervical dysplasia.
Ribaldone R; Boldorini R; Capuano A; Arrigoni S; Di Oto A; Surico N
Arch Gynecol Obstet; 2010 Aug; 282(2):193-7. PubMed ID: 20012636
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of mRNA HPV tests as a predictor of recurrence of precursor lesions and cervical cancer after conization: a systematic review and meta-analysis.
Macedo ACL; Borba CDLM; Bavaresco DV; Colonetti T; Grande AJ; Rosa MID
Biomark Med; 2019 Apr; 13(6):497-506. PubMed ID: 30924676
[No Abstract] [Full Text] [Related]
12. Absence of dysplasia in the excised cervix by a loop electrosurgical excision procedure in the treatment of cervical intraepithelial neoplasia.
Ryu A; Nam K; Chung S; Kim J; Lee H; Koh E; Bae D
J Gynecol Oncol; 2010 Jun; 21(2):87-92. PubMed ID: 20613897
[TBL] [Abstract][Full Text] [Related]
13. Repeat conisation or HPV test? What should be done if histology of the primary conisation requires a second conisation?
Koiss R; Babarczi E; Jenei C; Göcze P; Horányi D; Siklós P
Eur J Gynaecol Oncol; 2012; 33(2):134-7. PubMed ID: 22611949
[TBL] [Abstract][Full Text] [Related]
14. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer.
Castle PE; Dockter J; Giachetti C; Garcia FA; McCormick MK; Mitchell AL; Holladay EB; Kolk DP
Clin Cancer Res; 2007 May; 13(9):2599-605. PubMed ID: 17473189
[TBL] [Abstract][Full Text] [Related]
15. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
16. The residual rate of HPV and the recurrence rate of CIN after LEEP with negative margins: A meta-analysis.
Lin Y; Long Y; He J; Yi Q
PLoS One; 2024; 19(3):e0298520. PubMed ID: 38484015
[TBL] [Abstract][Full Text] [Related]
17. HPV16 persistent infection and recurrent disease after LEEP.
Bruno MT; Cassaro N; Garofalo S; Boemi S
Virol J; 2019 Nov; 16(1):148. PubMed ID: 31775792
[TBL] [Abstract][Full Text] [Related]
18. The Value of Partial HPV Genotyping After Conization of Cervical Dysplasias.
Friebe K; Klapdor R; Hillemanns P; Jentschke M
Geburtshilfe Frauenheilkd; 2017 Aug; 77(8):887-893. PubMed ID: 28845053
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of E6/E7 mRNA HPV Is a Prognostic Biomarker for Residual Disease Progression in Women Undergoing LEEP for Cervical Intraepithelial Neoplasia 3.
Bruno MT; Bonanno G; Sgalambro F; Cavallaro A; Boemi S
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686479
[TBL] [Abstract][Full Text] [Related]
20. Platelet-to-Lymphocyte Ratio (PLR) as the Prognostic Factor for Recurrence/Residual Disease in HSIL Patients After LEEP.
Huang G; Gao H; Chen Y; Lin W; Shen J; Xu S; Liu D; Wu Z; Lin X; Jiang T; Dong B; Sun P
J Inflamm Res; 2023; 16():1923-1936. PubMed ID: 37152868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
